Member Info for goldust88

Well I think share price has got a bit high for now with some bad news about spare parts gaining momentum and I expect more to come.

News on smaller reactors still some months away and the share price has already come up a long way.

I expect share price to drop away from here and come back in a couple of months.

The deal with Haleon in the States really is brilliant.

Haleon has Gsk and Pfizer as shareholders. Pfizer is the owner of Viagra.

So now Pfizer has now effectively tied up all treatments in the ED marketplace and can offer what anybody wants.

Brilliant. And now we are informed that at the moment demand is outstriping supply in some areas. Just wait and see what happens as soon as promotion and supply happens in the States.

Well I wouldn't wait before investing or you will be too late !

Yes this is far to cheap and will rise throughout the year to a more sensible share price.

On the cusp of MED3000 commercialisation

Please find attached our Update report on Futura Medical, a R&D-driven small pharma with a novel proprietary transdermal delivery system, DermaSys, and lead programme, MED3000 in erectile dysfunction, following a number of key events this year.
TRINITY DELTA VALUATION
Download full report here (mobile friendly).
Symbol FUM (AIM London)
Price 40.2p (£115.6m)
Date 10 November 2022
During 2022 Futura Medical successfully delivered on several key MED3000 related events, including the highly positive FM71 longer-term clinical data, which are needed to enter the US market and importantly reinforced MED3000’s differentiated and rapid onset of action. In addition, a number of commercial deals were executed, notably the European and UK deal with Cooper Consumer Health. The next steps are EU launches (due to start during H123), FDA marketing clearance (potentially by end Q123), and securing a US partner. These should be the final elements in converting MED3000 into a revenue generating OTC product for ED, transforming Futura Medical’s prospects. Pending visibility on both US and European launches, our updated model conservatively does not include any near-term MED3000 related revenues. Our Futura Medical valuation is now £270m, equivalent to 94p per share.

Its big jump in share price for this tiddler-looks like some very good news coming soon !

Well we have dropped a bit in price of late, however a bit of good news and this could soar.
A number of deals around the world have been announced with distributers and soon we may have news from them about how they are progressing.
In addition to that we have yet to see any deals announced for our local patch of the Uk & Europe.
I am expecting that a or some deals will be announced shortly for the UK &Europe and will all the necessary approvals in place any deal could see a rapid availiblity of Erexon to the public.
Any news of this will send the price skyward.
So today's share price could be a real bargain and seeing the web site up and running recently in readiness to me this indicates that some news on this front is shortly due.
So watch this space !

So lambooth ,you think you know more than Trinity Delta---with a head that big it must be difficult getting into the computer room to reply.
Clearly Futura are going along carefully selecting partners who will get the success for Futura in their own markets, in a sensible manner, each one funding their own costs and also making small payments to Futura.
As for the forecasts-they may be a few years old, but how do you know they are outdated-the fact is the demand may be even greater! And lets face it a lot of people who do not have a problem will want to try it out and that's not factored in.
In addition to that, once the product is available it will be over the internet and media across the world. I hope no one photographs the results and uploads it to the internet-but you never know.

Updated valuation is £264m (92p/share) We value Futura Medical using a risk-adjusted DCF model with conservative assumptions. We reinstate our valuation following the equity raise, reflecting progress and signing of new collaborations; our new valuation is £264m, equivalent to 92p per share
research@trinitydelta.org

The results here are excellent and it show how diverse the company is and how well it is doing in getting orders for their stuff.
I think that this is a somewhat overlooked stock-as can be seen by the number of posters here. I am keeping tight hold of my shares as my view is that it will be picked up by the tipster and funds. I expect it to be twice todays price in a years time.
So consider carefully before you sell or if you haven't any get a few.

Brokers view for next year is an estimated turnover of £23.7m and a massive increase in profits to £5.3m, giving some 1.8p per share in earnings.
They consider that current and prospective capital spend will still leave the group with £2.3m in cash at the end of this year and then £6.5m at end-2022.
The market is suddenly awake
Yesterday’s news was like an explosion.
The potential in this little ‘penny stock’ has now been identified – weeks after Master Investor readers were alerted and months after Andrew Simms’ comments on behalf of Arden Partners clients.
The average dealing volume in the shares has been around 250,000 for some while, despite sudden flurries up to 750,000 dealt in one day.
However, yesterday the dealings were a massive 83m shares traded, closing at 5.75p, up 40% on the day.
My View
There will be hiccups along the way, with big swings in either direction, but I consider that these shares are now heading up to scale the 10p barrier.
Arden has a ‘buy’ note out on the company, looking for 19p as their price objective.

The share issue has gone very well with Futura fully funded and price moving up nicely.
Now the issue of lack of cash is out of the way I expect that the share to be tipped shortly or indeed some news of a deal or deals.

Bogle & Booth---the dumber and dumber act.
Now that Covid restrictions have eased, would you please go on a long holiday to some far destination and give us all some peace from your constant rantings. We have heard it all before-many times and its incredibley boring for all.

OH NO !
Looks like a double act has arrived
-BOGLE and BOOTH
both Newbies to LSE.

Well seems like placing done and retail offer all fully taken up-that's £12million ( less costs) in the bank and fully funded for next 12 months.
This places Futura in a superb position and they can now negotiate from a position of strength enabling better deals to be done.
Whilst share price may drop in the very short term this removes all uncertainty and I look forward to the share price moving constantly upwards until deals come in and then some real share price rockets.
Good luck to all holders.

I always thought you were a bit queer Liambooth but I would advise against using Harami candles.

Well i did say a couple of days ago that I had cashed in as I thought the price was a bit high.
Now you can see why-it had been pumped up for a fundraising. Areal shame for recent investors as
Its certainly dropped from the recent high
-maybe nows the best time to get back in ?

It doesn't matter what you may write Liam-Futura will be a winner.
They have carried out the trials, proved that MED works very effectively, have the backing of a large number of the worlds leading experts, have gained european approval, have licenced the product in China and Asia and are now in commercial discussions with European and other countries. That is not bad going.
Whilst they may have made mistakes in the past they have learned from those and are now on the brink of massive success.
You should be looking forward not backward or perhaps you are just a backward person. Which I suspect is what you are.
All of us on here are fed up with the daily rubbish you print, so do us all a favour and go and join another thread with your doom and gloom, you are like covid, a right bit of a pest, but you will be beaten soon.

Well it seems I left the party to early after making a few bob as I thought it was overpriced-obviously I was wrong-just look at the rise today.
Good luck to all holders.

From RNS---The share price of 28.3 pence at the 31 March 2021 close represents a premium of 352.8% to the NAV per share.
Can anyone explain to me why share price is so far above value ?
It seems to me that this share is in for an almighty share price fall some time soon.

Simon Cawkwell, AKA Evil Knievil on MASTER INVESTOR comments
" Futura Medical (LON:FUM) might at very long last be on the brink of commercial proceeds for its erectile dysfunction gel. If these emerge, anything below 100p will make FUM look very cheap"
Well this guy is pretty shrewd at both gambling and investment and has made a load of money over the years-he doesn't tip anything unless he thinks its a winner.